Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» JPMHC 2025
JPMHC 2025
[podcast]What to expect from the biotech IPO market in 2025
Fierce Biotech
Fri, 01/31/25 - 11:18 am
biotech
IPOs
JPMHC 2025
The biopharma industry outlook on 2025: Uncertainty and change
BioPharma Dive
Sun, 01/26/25 - 04:16 pm
biotech
JPMHC 2025
China
regulatory
Donald Trump
JPM25: Incyte plans to turn 'a lot of cards' in 2025 as CEO eyes 2 types of deals
Fierce Pharma
Wed, 01/22/25 - 07:24 pm
JPMHC 2025
Pharma CEOs
Incyte
Hervé Hoppenot
JPM25 Recap: The Medtech Moments That Have the Industry Buzzing
Medical Devices and Diagnostics Industry
Tue, 01/21/25 - 07:10 pm
Medtech
JPMHC 2025
Illumina
PFA
JNJ
Medtronic
Boston Scientific
CGMs
Intuitive Surgical
robotic surgery
Embecta
renal denervation
JPM25: The FDA’s future, AbbVie’s second thoughts and Lilly’s lesson
BioPharma Dive
Fri, 01/17/25 - 11:30 am
JPMHC 2025
AbbVie
Eli Lilly
JP Morgan 2025: Radiopharmaceuticals M&A fuels Telix’s busy year
Pharmaceutical Technology
Fri, 01/17/25 - 11:28 am
Telix Pharmaceuticals
JPMHC 2025
radiopharmaceuticals
JPM25: Emergent secures licensing deal for opioid overdose spray amid recovery plan
Fierce Pharma
Thu, 01/16/25 - 11:17 am
JPMHC 2025
Emergent BioSolutions
opioid overdose
Kloxxado
Narcan
JPM25: Bayer gears up for 'must-win battles' as Xarelto's decline is in full swing, pharma chief says
Fierce Pharma
Thu, 01/16/25 - 11:16 am
Bayer
Xarelto
JPMHC 2025
By the numbers: J&J, GSK lead J.P. Morgan deal announcements in 2025, the largest turnout in years
Pharma Voice
Thu, 01/16/25 - 11:02 am
JPMHC 2025
M&A
JNJ
Intra-Cellular Therapeutics
GSK
IDRx
JP Morgan 2025: AbbVie counts on Skyrizi and Rinvoq to fill Humira-sized hole
Clinical Trials Arena
Wed, 01/15/25 - 11:54 pm
JPMHC 2025
AbbVie
Skyrizi
Rinvoq
Humira
JPM25: Takeda spotlights 6 pipeline assets that could pull down up to $20B in collective peak sales
Fierce Pharma
Wed, 01/15/25 - 11:52 pm
Takeda
JPMHC 2025
Under pressure to deal, Biogen executives deflect urgency at JPM25
BioSpace
Wed, 01/15/25 - 11:33 am
Biogen
JPMHC 2025
M&A
Chris Viehbacher
SAGE Therapeutics
Boston Scientific ups PFA forecast, targets market leadership
Medtech Dive
Wed, 01/15/25 - 11:21 am
Boston Scientific
Medtech
JPMHC 2025
pulsed field ablation
PFA
Farapulse
JPM25, Day 3: GSK’s liver disease plans, the Biotech CEO Sisterhood, and more
Fierce Biotech
Wed, 01/15/25 - 11:08 am
JPMHC 2025
GSK
Biotech CEO Sisterhood
JPM25: GSK, Sanofi CEOs welcome 'transparency' in response to anti-vaccine movement in US
Fierce Pharma
Tue, 01/14/25 - 06:21 pm
JPMHC 2025
Pharma CEOs
Sanofi
Paul Hudson
GSK
Emma Walmsley
vaccines
JPM25, Day 2: Pharma should 'run towards' vaccine efficacy conversations, says GSK CEO
Fierce Biotech
Tue, 01/14/25 - 06:06 pm
JPMHC 2025
vaccines
JPM25: After BridgeBio touts 'remarkable' early uptake for its Vyndaqel rival, analysts hail Attruby's debut as a 'launch to own'
Fierce Pharma
Tue, 01/14/25 - 11:21 am
JPMHC 2025
BridgeBio
Vyndaqel
Attruby
Healthcare dealmakers eye M&A resurgence in second Trump term
US News and World Report
Tue, 01/14/25 - 11:18 am
M&A
JPMHC 2025
Donald Trump
JP Morgan 2025: NVIDIA partners with IQVIA, Illumina and Mayo Clinic
Clinical Trials Arena
Tue, 01/14/25 - 10:07 am
JPMHC 2025
NVIDIA
IQVIA
Illumina
Mayo Clinic
artificial intelligence
JP Morgan 2025: reduced dosing and expanded manufacturing paving way for Amgen’s obesity entrance
Clinical Trials Arena
Tue, 01/14/25 - 09:54 am
JPMHC 2025
Amgen
obesity
Robert Bradway
MariTide
Pages
1
2
next ›
last »